JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Close to two years after Juno Therapeutics disappeared from Nasdaq, a CAR-T biotech it spawned is settling on a stock exchange on the other side of the globe.
JW Therapeutics, a joint venture between Juno and WuXi AppTec, raised $300 million in its IPO on the Hong Kong Stock Exchange — building on $190 in venture money since launching in 2018.
The pitch is all about bringing cell therapy breakthroughs to China, tapping into American connections that extend into Lyell, a new startup led by Juno co-founder Rick Klausner, and Eureka, a longtime partner of Juno. WuXi, a global CRO, brings expertise in process development and manufacturing to the mix.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.